摘要
目的探讨不同剂量瑞舒伐他汀对经皮冠脉介入术后对比剂肾病的影响。方法连续入选2011-05～2012-09在高州市人民医院心内科住院拟行择期经皮冠脉介入术(PCI)的患者240例,所有患者按1∶1比例分为强化治疗组(A组)及常规治疗组(B组)。A组:在术前及术后给予瑞舒伐他汀20 mg/d,共30 d;B组术前及术后给予常规剂量10 mg/d,共30 d;对比剂肾病(CIN)定义为:在使用对比剂后的72 h内,血清中肌酐浓度升高>0.5 mg/dL(>44 mol/L)或者较原基础值升高25%以上。结果本研究240例患者,共28例发生CIN,总发生率达11.7%。其中强化治疗组(A组)CIN发生率明显低于常规治疗组(B组),且两组间差异具有统计学意义(10%VS 13%,χ2=0.458,P=0.002)。两组在术后院内临床事件包括需要肾脏替代治疗、死亡率、需要IABP治疗等方面具有显著差异(P<0.05)。结论术前及术后给予瑞舒伐他汀强化治疗,能够显著减少CIN的发生,同时减少院内不良事件发生。
Objective To evaluate the efficacy of treatment with rosuvastatin in different dosage on contrast induced nephropathy(CIN) developed after percutaneous coronary intervention(PCI).Methods Randomly selecting 240 patients undergoing percutaneous coronary intervention to accept rosuvastatin 20 mg or rosuvastatin 10 mg before and after the procedure.CIN was defined as an absolute increase of serum creatinine>44.2 μmol/L within 48~72 hours after the procedure.Results CIN occurred in 28(11.7%) patients among 240 patients,12(10%) in the intensive treatment group and 16(13%) in the routine group(P=0.002).There was significant difference between two groups in incidence of requiring renal-replacement therapy,in-hospital death,requiring intra-aortic balloon pump(IABP) and so on.Conclusion In this randomized trial,it is found that rosuvastatin reduces the risk of contrast-induced nephropathy or other clinically relevant outcomes in patients undergoing percutaneous coronary intervention.
出处
《黑龙江医学》
2013年第3期164-166,共3页
Heilongjiang Medical Journal
关键词
对比剂肾病
经皮冠脉介入术
瑞舒伐他汀
Contrast-induced nephropathy
Percutaneous coronary intervention
Rosuvastatin
